Neurological Manifestations of Arsenic Intoxication

Back

Background

The atomic number of arsenic, an element, is 33, and its atomic weight is 74.91. A commonly found form of arsenic is gray with a metallic appearance. Yellow, brown, and black forms are also known. When arsenic is heated, it sublimes, that is, it changes directly into the gaseous form, arsine. Arsenic is considered a transitional element intermediate between metals and nonmetals, but it classically is considered a heavy metal. It has been known since ancient times and has been and continues to be used medicinally.[1]

Arsenical pesticides are still used in some areas in agriculture. Chronic toxicity from ingestion or inhalation of arsenic may be occupational or environmental.[2, 3, 4, 5] Wells drawing from watersheds near old mines may be contaminated with dangerous amounts of arsenic.[6] Accidental ingestion, ingestion with suicidal intent, and intentional poisoning most commonly are associated with acute toxicity. With regular and long-term exposure, some tolerance may develop. At one time, people in southern Austria reportedly found that eating arsenic had a "tonic" effect and were able to ingest without toxicity what would usually be a fatal dose.

Documented cases of arsenic poisoning have been associated with ingestion of traditional Chinese herbal balls, Korean herbal preparations used to treat hemorrhoids, and kelp supplements. Arsenic is sometimes found in homeopathic preparations containing sulphur. Arsenic is used to treat and preserve lumber. As early as the 1890s, arsenical pigments were used in wallpaper both for coloring and for its antifungal properties. The action of the fungus Penicillium brevicaule releases arsine. Arsenic was used to strengthen lead and, in the glassmaking industry, to reduce discoloration caused by trace amounts of iron. All of these applications add to the hazards of old house restorations. Arsenic was used as a poison gas called lewisite in World War I; hence, the name of the agent used to treat arsenic intoxication is British antilewisite (BAL).[7, 8]

Pathophysiology

Acute exposure

Inorganic arsenicals, such as the trioxide, a by-product of smelting of ore containing copper, lead, and zinc, are more toxic than the organic. Arsenic may be inhaled in particulate form, ingested, or absorbed through skin and mucous membranes. The minimum lethal dose is 100–200 mg of arsenic trioxide.

Exposure to a toxic dose initially produces a dry burning sensation in the mouth and throat and a constricted feeling in the throat. This is followed by severe abdominal pain, cramping, diarrhea, and vomiting. The diarrhea begins with "rice water" stools progressing to a bloody discharge. Stools and breath may have a garlicky odor. Vertigo develops, followed by delirium, coma, and often convulsions. Circulatory collapse with hepatic and renal failure ensues. Myocardial toxicity involves broadening of the QRS, flattening of the T waves, and ST depression. In acute exposure to the gaseous form, inhalation of toxic amounts of arsine gas results in headache, malaise, weakness, dizziness, and dyspnea accompanied by gastrointestinal distress.

The effect is not immediate but typically is delayed by 2–24 hours. Usually, hemolysis occurs 4–6 hours after the onset of symptoms and dark red urine is noticed. Jaundice develops 24–48 hours later. Patients present to the emergency department with severe jaundice, anemia, and hemoglobinuria (ie, blackwater urine). On admission, the patient may have fever, tachycardia, and tachypnea. Acute oliguric renal failure occurs because concentration of arsenic in the proximal tubules and binding to proteins of tubular epithelium damages the tubules. Treatment involves hemodialysis and the use of BAL (Dimercaprol).

Subacute and chronic exposure

Chronic exposure, as in well water, has been associated with bladder cancer and risk of diabetes with neuropathy. In children, there have been reports of decreased intelligence quotients. 

Arsine was identified in 1775. The first reported fatality from arsine inhalation was in 1815 when a German chemist died after inhaling the gas in his laboratory. Workers in the metallurgy industry are at a risk of repeated exposure to arsine gas. The action of acid on metal ore contaminated with arsenic causes release of arsine gas. Arsenic-containing dust emitted from smelters is another source.[2]

Environmental exposure to well water containing inorganic arsenic can result in skin hyperpigmentation or an eczematous dermatitis.[9, 10] Peripheral vascular involvement may occur, with acrocyanosis and the appearance of a Raynaud-like picture. In addition, a sensorimotor distal neuropathy may occur that presents like Guillain-Barré syndrome,[11] and sideroblastic anemia—a state of ineffective erythropoiesis characterized by a significant number of erythroid precursors containing mitochondria with stainable iron granules—also may be noted. Although a similar hematopoietic picture is seen in lead toxicity, the mechanism producing the anemia is not believed to be the same. Leukopenia is a common finding.

Biochemistry of arsenicals

Many enzyme systems are vulnerable to the tendency for arsenicals to react with sulfhydryl groups. The pyruvate and succinate oxidation pathways may be disrupted. The sulfhydryl cofactor dihydrolipoate appears to be the principal site of inhibition. The converting enzyme dihydrolipoate dehydrogenase is also susceptible. This inhibition effectively blocks the Krebs cycle, interrupting oxidative phosphorylation, which results in marked depletion of ATP stores. Arsenic also produces a picture of thiamine deficiency by preventing transformation of thiamine into acetyl-coenzyme A (CoA) and succinyl-CoA. Since alcohol affects the same cycle, arsenic toxicity is accentuated by alcohol ingestion. A number of other enzyme systems are susceptible, but they are of minor clinical significance.

Arsenolysis, another mechanism of toxicity, results when arsenic anions disrupt oxidative phosphorylation by replacing stable phosphoryl with less stable compounds. Unstable arsenic compounds irreversibly decompose, resulting in loss of high-energy phosphate bonds. The cell then self-destructs in an attempt to restore lost energy.

Medicinal uses of arsenicals

Inorganic arsenic has been used in medicine for over 2500 years. The most widely used form was Fowler solution containing 1% potassium arsenite, which was used for treatment of psoriasis. Arsphenamine was for many years the standard treatment for syphilis. Melarsoprol is an organoarsenic compound used to treat infections caused by Trypanosoma brucei or Trypanosoma gambiense. Retrospective studies have suggested an increase in the incidence of hepatic angiosarcoma in people previously treated with Fowler solution, but evidence is tentative. Regular, long-term arsenic exposure has been associated with various cutaneous carcinomas as well as internal malignancies including bronchogenic carcinoma and hepatocellular carcinoma.[12, 13]

Epidemiology

Frequency

United States

In 1998, American Association of Poison Control Centers (APCC) reported 956 cases that were not related to pesticides. Ninety-nine cases involved exposure to arsenic-containing pesticides; 4 of the nonpesticide cases died, while no death was reported from the pesticide-related cases. Estimating the number of unreported cases is difficult. One estimate is that 900,000 people a day are exposed to arsenic particularly in areas where well water is extensively used.[14]  An arsenic level of greater than 10 micrograms/liter is considered excessive by most state authorities. According to the US Geological Survey, arsenic levels in bedrock well water have been found at a rate greater than 3x the national average along a corridor stretching from eastern Maine to northern Massachusetts.[15] The US Geological Survey found that within a belt of mata sedementary bedrock in a corrridor from eastern Maine through northern New Jersey and southern New York, significant levels of arsenic have been found in up to 23% of wells. In Maine, 10% of all wells have been found to have elevated levels.

International

In 1955, in Japan, 12,000 people were poisoned after consumption of powdered milk contaminated with arsenic; 131 people died. Arsenic exposure from drinking water is a worldwide problem, especially in Bangladesh, where beginning in the 1970s, 10 million hand-pumped wells were installed to prevent water-borne diseases. It was not appreciated that the water was contaminated with arsenic until 20 years later. Four hundred and seven deaths were attributed to arsenic between October 2000 and February 2009.[16] Similarly, arsenic is a known public health problem in India, Chile, Taiwan, Argentina, and Mongolia. Clusters of cases of bladder cancer in residents of the north coast of Chile were found to be 4-5 times the rate in other regions in Chile.[17]

Mortality/Morbidity

Fortunately, the known mortality rate is low—4 reported in 1998 and only sporadic cases in prior years.

Race-, sex-, and age-related demographics

No racial predilection is apparent.

Industrial exposures to arsenic are more likely to involve men.[18] The same may be said for exposure to arsenical preparations used in agriculture, construction, and forestry. Intentional poisonings involve both sexes. No hormone-related difference in the metabolism of arsenic is known.

Most cases of exposure are in adults.

Patient Education

Public awareness of dangerous arsenic levels has somewhat improved in the United States because of the vigilance of State Housing Authorities and the US Geological Survey. A number of companies, especially in the northeast are able to treat the water to reduce arsenic levels in wells.  Anyone planning to purchase property in areas where the water supply is a private well must have the water tested for arsenic levels in addition to other contaminents.

History

Acute toxicity following ingestion, inhalation, or absorption of inorganic arsenic produces a burning sensation in the mouth and throat. This is followed, usually somewhat later, by severe gastrointestinal distress with copious and severe diarrhea and vomiting. Vertigo, delirium, coma, and often convulsions are seen as the toxicity is manifest. Circulatory collapse and renal and hepatic failure ensue, and hemolysis usually occurs 4-6 hours after onset of evidence of toxicity. Acute symptoms typically develop hours after exposure to inorganic arsenic. Inhalation of arsine gas produces headache, malaise, weakness, dizziness, dyspnea, and GI distress more rapidly.

The typical picture in subacute arsenic toxicity includes the onset of gastrointestinal symptoms—nausea, vomiting, and diarrhea—which may be intermittent but in retrospect are associated with ingestion of hot or cold beverages. For a layperson's account of an experience with arsenic poisoning, read "My Husband Poisoned Me" by Ellen Harris in the March 2000 issue of McCall's Magazine, pages 68-73.

Chronic exposure effects should be suspected when a patient presents with a distal sensorimotor neuropathy accompanied by skin hyperpigmentation. History of drinking well water is an additional clue. Bae et al have written on the role of a rice cooking technique associated with arsenic toxicity in Bangladesh.[3]

Physical

Heavy metal poisonings have many similarities, making clinical distinctions between them difficult at times. Arsenic is more likely than other heavy metals to produce a dramatic gastroenteric picture when ingested. Inhalation of arsine gas produces clinical features whose onset is dependent on the degree of exposure. The initial complaints may be vague, with headache, malaise, weakness, dizziness, and dyspnea. Later, the features are the same as those seen in inorganic arsenic ingestion. The cutaneous manifestations are rather different depending on the heavy metal exposure.

Laboratory Studies

Testing for arsenic

Inorganic arsenic exists in various forms. The most toxic are As-III and As-V. Detoxification occurs as As-III is oxidized in the liver to As-V and then methylated to dimethylarsine and monomethylarsine over the course of 24 hours. As-III and As-V levels in the urine peak at about 10 hours and return to normal 20-30 hours after acute ingestion; the methylated compounds peak at 40-50 hours and can be measured as long as 20 days after ingestion. Blood levels are not useful. The biological half-life of inorganic arsenic is only 2 hours so blood or serum arsenic is unlikely to be detected after 2-4 hours.

Organic arsenic of a nontoxic variety is present in shellfish and saltwater fish, such as haddock or cod. The arsenobetaine and arsenocholine in seafood are excreted completely in the urine within 1-2 days. The urine of a person consuming seafood within 1-2 days of testing is likely to contain 50-2000 mcg of arsenic. Actual arsenic toxicity is characterized by the excretion of 500-50,000 mcg/day. In 41 cases of arsenic-induced peripheral neuropathy, most patients had total 24-hour urine concentrations of 100-400 mcg. A method has been developed to fractionate the inorganic and organic species using a cation-exchange cartridge and then analyzing the fractions using spectrophotometry.[21] Of historical interest, the earliest test for arsenic was developed by the English chemist James Marsh (1794-1846).

Imaging Studies

Upper GI radiography after acute ingestion may show radiopaque material in the upper GI tract, as it does in pica (ie, ingestion of inappropriate materials) involving other heavy metals. Maximal absorption of arsenic occurs in the small intestine.

CT scans and MRIs of the brain may show the cerebral edema and hemorrhagic or ischemic changes associated with acute toxicity.

Other Tests

Electrodiagnostic testing

Motor and sensory nerve conduction velocities, visual evoked potentials, and somatosensory evoked potentials may be helpful in monitoring the progress of treatment. The neuropathy is axonal in nature with some demyelination.

Electromyography shows denervation potentials and reduction in motor unit activity. High-amplitude, polyphasic motor units are seen. A myelopathy may develop and anterior horn cell abnormalities may suggest amyotrophic lateral sclerosis.

Following acute exposure, axonal degeneration and progressive slowing of sensory and motor conduction velocities plateaus and begins to improve after treatment. In chronic, low-level exposure, a distal, axonal, primarily sensory neuropathy develops. This is a duration-dependent sensorimotor neuropathy that affects all sensory modalities but includes severe loss of large-fiber sensation (ie, position and vibration sense).

Cranial nerves are spared.

Electroencephalography

Electroencephalography may be useful in monitoring any encephalopathy or seizures associated with acute toxicity. No EEG finding is pathognomonic for arsenic toxicity.

Histologic Findings

Nerve biopsies of people who have arsenical neuropathy show degenerated fibers and reduction of myelinated fibers in particular, but axons of all sizes are absent or markedly fragmented. Spinal cord pathways and anterior horn cells may be affected. In chronic toxicity, varying degrees of nerve fiber regeneration may be observed. Acute encephalopathic changes seen in the brain include perivascular hemorrhage. The chief mechanism is cerebral edema and vascular occlusion.

Medical Care

The patient who presents with acute exposure is usually in severe distress. Hydration is vital in managing dehydration that can rapidly lead to hypovolemic shock because of the severity of the vomiting and diarrhea. If the patient is not actively vomiting, consider lavage with warm water or (some suggest) 1% solution of sodium thiosulfate. Whole bowel irrigation with polyethylene glycol may reduce or prevent continued absorption of arsenic that has passed the stomach. Chelation therapy should be started immediately.

Consultations

See the list below:

Diet

During the acute phase, when the patient is vomiting and having diarrhea, parenteral fluids are indicated. After the patient's condition stabilizes, oral intake may be allowed as tolerated. If circumstances are suspect, the patient should not be served any food or drink from home.

Activity

Activity is dependent on the patient's level of alertness and intactness of the peripheral nervous system.

Medication Summary

The treatment of acute toxicity from arsenic consists primarily of maintaining hydration and electrolyte balance. The use of chelating agents hastens the removal of arsenic from the system. Management of arsine toxicity generally addresses the acute hepatorenal complications. The use of chelating agents in these cases is debatable.

Dimercaprol (BAL in Oil)

Clinical Context:  British antilewisite is agent of choice in United States. Used as chelator for other heavy metals and stocked as essential item in emergency departments and poison control centers.

Succimer (Chemet)

Clinical Context:  Licensed by FDA as chelating agent for lead poisoning in children; used successfully to treat arsenic intoxication as well; available as 100-mg capsule.

Penicillamine (Cuprimine, Depen)

Clinical Context:  Metal chelator used to treat arsenic poisoning; forms soluble complexes with metals excreted in urine.

Class Summary

These are substances that bind heavy metals in the plasma and render them nontoxic; they also aid in their excretion.

Further Outpatient Care

See the list below:

Inpatient & Outpatient Medications

See the list below:

Transfer

See the list below:

Deterrence/Prevention

See the list below:

Complications

See the list below:

Prognosis

See the list below:

Author

Frances M Dyro, MD, Associate Professor of Neurology, New York Medical College; (Retired) Physician, Department of Neurology, Westchester Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD, Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University in St Louis School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Disclosure: Nothing to disclose.

Chief Editor

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS, Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Jonathan S Rutchik, MD, MPH, FACOEM, Associate Clinical Professor, Division of Occupational Medicine, Department of Medicine, University of California, San Francisco, School of Medicine; Neurology, Environmental and Occupational Medicine Associates (www.neoma.com)

Disclosure: Nothing to disclose.

References

  1. Ford M. Arsenic. In: Goldfrank LR, Flomenbaum NE, et al, eds. Toxicologic Emergencies. 1994:1011-1029.
  2. Axelson O, Dahlgren E, Jansson CD, Rehnlund SO. Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. Br J Ind Med. 1978 Feb. 35(1):8-15. [View Abstract]
  3. Bae M, Watanabe C, Inaoka T, et al. Arsenic in cooked rice in Bangladesh. Lancet. 2002 Dec 7. 360(9348):1839-40. [View Abstract]
  4. Franzblau A, Lilis R. Acute arsenic intoxication from environmental arsenic exposure. Arch Environ Health. 1989 Nov-Dec. 44(6):385-90. [View Abstract]
  5. Heinrich-Ramm R, Mindt-Prufert S, Szadkowski D. Arsenic species excretion in a group of persons in northern Germany-- contribution to the evaluation of reference values. Int J Hyg Environ Health. 2001 Jul. 203(5-6):475-7. [View Abstract]
  6. Ball P. Arsenic-free water still a pipedream. Nature. 2005 Jul 21. 436(7049):313. [View Abstract]
  7. Fowler BA, Weissberg JB. Arsine poisoning. N Engl J Med. 1974 Nov 28. 291(22):1171-4. [View Abstract]
  8. Heyman A, Pfeiffer JB, Willett RW, Taylor HM. Peripheral neuropathy caused by arsenical intoxication; a study of 41 cases with observations on the effects of BAL (2, 3, dimercapto-propanol). N Engl J Med. 1956 Mar 1. 254(9):401-9. [View Abstract]
  9. Chen CJ, Wu MM, Lee SS, et al. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988 Sep-Oct. 8(5):452-60. [View Abstract]
  10. Watanabe C, Kawata A, Sudo N, et al. Water intake in an Asian population living in arsenic-contaminated area. Toxicol Appl Pharmacol. 2004 Aug 1. 198(3):272-82. [View Abstract]
  11. Donofrio PD, Wilbourn AJ, Albers JW, et al. Acute arsenic intoxication presenting as Guillain-Barre-like syndrome. Muscle Nerve. 1987 Feb. 10(2):114-20. [View Abstract]
  12. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol. 1992 Mar 1. 135(5):462-76. [View Abstract]
  13. Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer. A reanalysis. Am J Epidemiol. 1987 Jun. 125(6):929-38. [View Abstract]
  14. Karagas MR, Le CX, Morris S, et al. Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int J Occup Med Environ Health. 2001. 14(2):171-5. [View Abstract]
  15. Ayotte JD, Medalie L, Qi SL, Backer LC, Nolan BT. Estimating the High-Arsenic Domestic-Well Population in the Conterminous United States. Environ Sci Technol. 2017 Nov 7. 51 (21):12443-12454. [View Abstract]
  16. Argos M, Kalra T, Rathouz PJ, Chen Y, Pierce B, Parvez F, et al. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet. 2010 Jul 24. 376(9737):252-8. [View Abstract]
  17. Barbara Fraser. Cancer cluster in Chile linked to arsenic contamination. The Lancet. February 18, 2012. 379:603.
  18. Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006 Dec 16. 368(9553):2167-78. [View Abstract]
  19. Kyle RA, Pease GL. Hematologic aspects of arsenic intoxication. N Engl J Med. 1965 Jul 1. 273:18-23. [View Abstract]
  20. Massey EW. Arsenic neuropathy. Neurology. 1981 Aug. 31(8):1057-8. [View Abstract]
  21. Moyer TP. Testing for arsenic. Mayo Clin Proc. 1993 Dec. 68(12):1210-1. [View Abstract]
  22. Lee AM, Fraumeni JF Jr. Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst. 1969 Jun. 42(6):1045-52. [View Abstract]
  23. Neubauer O. Arsenical cancer. Br J Cancer. 1947. 1:192-251: